Added to YB: 2026-01-06
Pitch date: 2026-01-03
OMER [bullish]
Omeros Corporation
-17.35%
current return
Author Info
No bio for this author
Company Info
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Market Cap
$1.2B
Pitch Price
$16.37
Price Target
49.10 (+263%)
Dividend
N/A
EV/EBITDA
-12.44
P/E
-8.14
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
OMER: Yartemlea Alone Worth More Than Today’s Market Cap
OMER: FDA approved Yartemlea 12/24 for bone marrow transplant infections, replacing $600k AstraZeneca drug. Expecting $400k pricing vs stale $125-200k estimates. 1,500 patients = $600M revenue, 4x multiple = $2.4B value vs $1.5B market cap. Add Europe/Japan + $1B Novo deal = potential double/triple in 12-18 months.
Read full article (2 min)